Key result
IV flecainide for AF triggers extreme bradycardia and cardiac arrest in a case report.
Case Report (n=1)
No
This case report highlights the severe risk of cardiac arrest associated with flecainide infusion for pharmacologic cardioversion of atrial fibrillation.
May warrant caution with IV flecainide for AF cardioversion in elderly patients; leaves open need for prospective safety data.
Flecainide is a class I antiarrhythmic used for supraventricular tachyarrhythmias with mild adverse reactions.We present a case report in a 78-year-old male that came to the emergency department with atrial fibrillation and was subsequently treated with flecainide. During the infusion, the patient went into cardiac arrest. Cardiopulmonary resuscitation was performed until the return of spontaneous circulation was achieved after 1 min and 40 seconds. Conclusion. Some trials, like The Cardiac Arrhythmia Suppression Trial (CAST), consider flecainide to be safe, but our case report, together with several other published reports brings attention to the use of flecainide in pharmacologic cardioversion of atrial fibrillation as a cause of cardiac arrest.
No takes yet. Share an insight, caveat, or question.
Tiziana Ciarambino (2021) conducted a case report in Atrial fibrillation (n=1). Flecainide was evaluated on Cardiac arrest. Intravenous administration of flecainide for atrial fibrillation induced extreme bradycardia and subsequent cardiac arrest in a 78-year-old male patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: